<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4(11)</volume><submitter>Goldmann T</submitter><pubmed_abstract>Translational read-through-inducing drugs (TRIDs) promote read-through of nonsense mutations, placing them in the spotlight of current gene-based therapeutic research. Here, we compare for the first time the relative efficacies of new-generation aminoglycosides NB30, NB54 and the chemical compound PTC124 on retinal toxicity and read-through efficacy of a nonsense mutation in the USH1C gene, which encodes the scaffold protein harmonin. This mutation causes the human Usher syndrome, the most common form of inherited deaf-blindness. We quantify read-through efficacy of the TRIDs in cell culture and show the restoration of harmonin function. We do not observe significant differences in the read-through efficacy of the TRIDs in retinal cultures; however, we show an excellent biocompatibility in retinal cultures with read-through versus toxicity evidently superior for NB54 and PTC124. In addition, in vivo administration of NB54 and PTC124 induced recovery of the full-length harmonin a1 with the same efficacy. The high biocompatibilities combined with the sustained read-through efficacies of these drugs emphasize the potential of NB54 and PTC124 in treating nonsense mutation-based retinal disorders.</pubmed_abstract><journal>EMBO molecular medicine</journal><pagination>1186-99</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3494875</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation.</pubmed_title><pmcid>PMC3494875</pmcid><pubmed_authors>van Wyk M</pubmed_authors><pubmed_authors>Baasov T</pubmed_authors><pubmed_authors>Nagel-Wolfrum K</pubmed_authors><pubmed_authors>Goldmann T</pubmed_authors><pubmed_authors>Overlack N</pubmed_authors><pubmed_authors>Belakhov V</pubmed_authors><pubmed_authors>Wolfrum U</pubmed_authors><pubmed_authors>Moller F</pubmed_authors></additional><is_claimable>false</is_claimable><name>A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation.</name><description>Translational read-through-inducing drugs (TRIDs) promote read-through of nonsense mutations, placing them in the spotlight of current gene-based therapeutic research. Here, we compare for the first time the relative efficacies of new-generation aminoglycosides NB30, NB54 and the chemical compound PTC124 on retinal toxicity and read-through efficacy of a nonsense mutation in the USH1C gene, which encodes the scaffold protein harmonin. This mutation causes the human Usher syndrome, the most common form of inherited deaf-blindness. We quantify read-through efficacy of the TRIDs in cell culture and show the restoration of harmonin function. We do not observe significant differences in the read-through efficacy of the TRIDs in retinal cultures; however, we show an excellent biocompatibility in retinal cultures with read-through versus toxicity evidently superior for NB54 and PTC124. In addition, in vivo administration of NB54 and PTC124 induced recovery of the full-length harmonin a1 with the same efficacy. The high biocompatibilities combined with the sustained read-through efficacies of these drugs emphasize the potential of NB54 and PTC124 in treating nonsense mutation-based retinal disorders.</description><dates><release>2012-01-01T00:00:00Z</release><publication>2012 Nov</publication><modification>2025-04-04T10:11:35.131Z</modification><creation>2019-03-27T01:00:17Z</creation></dates><accession>S-EPMC3494875</accession><cross_references><pubmed>23027640</pubmed><doi>10.1002/emmm.201201438</doi></cross_references></HashMap>